Clinical Trials

April 24, 2025

Elritercept may effectively treat anemia in myelofibrosis patients. Learn about the latest RESTORE trial findings and its potential benefits.

April 15, 2025

Understanding how ROR1-targeted therapies work—and whether they apply to your specific blood cancer type—can help you make more informed treatment decisions.

February 07, 2025

What is navtemadlin, and how does this treatment in clinical trials help stop myelofibrosis cells and improve cancer-related symptoms?

February 03, 2025

Learn how anemia impacts survival in myelofibrosis patients treated with ruxolitinib. Discover key findings from the phase 3b JUMP study.

December 02, 2024

The SENTRY trial represents a large step forward for unmet needs of MF patients by treating them with selinexor.

November 20, 2024

Read about how a new polycythemia vera treatment in clinical trials called rusfertide is helping patients reduce the need for blood draws.

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

May 22, 2024

One of the largest trials in myelofibrosis is testing pelabresib with ruxolitinib and will be sharing new updates soon! Stay tuned!